



12 June 2025

The Board of directors
Visen Pharmaceuticals
Room 1919, 19/F
Lee Garden One
33 Hysan Avenue
Causeway Bay, Hong Kong

Dear Sir/Madam,

Visen Pharmaceuticals
(the “Company”, together with its subsidiaries, the “Group”)
Continuing connected transaction in relation to
the Commercial Supply Framework Agreement (the “Transaction”)

We are the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders of the Company in relation to the Transaction. Capitalised terms used herein shall have the same meanings as those defined in the supplemental circular of the Company dated 12 June 2025 (the “**Circular**”) in relation to, among other things, the Transaction.


We hereby confirm that as of the Latest Practicable Date, we have given and have not withdrawn our written consent to the issue of the Circular with the inclusion of our letter and references to our name in the form and context in which it appears.

As of the Latest Practicable Date, we did not have any shareholding in the Group or any right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in the Group.

As of the Latest Practicable Date, we did not have any interest, either directly or indirectly, in any assets that have been, since December 31, 2024 (being the date to which the latest published audited accounts of the Company were made up), acquired or disposed of by or leased to the Company, or were proposed to be acquired or disposed of by or leased to the Company.

[Signature page follows]

Yours sincerely,
For and on behalf of
Red Solar Capital Limited

A handwritten signature in black ink, consisting of a large 'L' followed by a cursive 'C' and a horizontal flourish.

Leo Chan
Managing Director